Eric K. Rowinsky, M.D., is the former head of research and development and chief medical officer of Stemline Therapeutics, Inc. and has served on the board of Biogen since 2010. Dr. Rowinsky is also an adjunct professor of medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the chief medical officer of Primrose Therapeutics, Inc. from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the chief medical officer and executive vice president of ImClone Systems Incorporated. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including director of the Institute and director of clinical research. From 1988 to 1996, Dr. Rowinsky was an associate professor of oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky is also a member of the boards of directors of Coronado Biosciences, Inc. and Navidea Biopharmaceuticals, Inc. Dr. Rowinsky earned his medical degree from Vanderbilt University School of Medicine and a fellowship in medical oncology from the Johns Hopkins University.
Mr. Rowland is the chief executive officer at Aurinia Pharmaceuticals and has more than 30 years of experience in financial management and strategic business operations. He served as the vice president and chief financial officer of ViroPharma Incorporated, an international biopharmaceutical company, until it was acquired by Shire plc in January 2014. He also served as senior vice president of finance, with responsibilities for leading the treasury, tax, investor relations and business planning groups. Prior to joining ViroPharma in 2008, Mr. Rowland was the executive vice president and chief financial officer, as well as the interim co-chief executive officer, for Endo Pharmaceuticals Inc., a specialty pharmaceutical company with a primary focus in pain management, where he served from 2006 to 2008. At Endo, Mr. Rowland drove the strategic planning process, including the design and implementation of the company’s mid and long-term strategy. From 2004 to 2006, Mr. Rowland was the senior vice president and chief financial officer of Biovail Corporation, an international pharmaceutical company, where he directed all financial activities for the company including tax, treasury, accounting, financial analysis, investor relations as well as all aspects of information technology. Mr. Rowland previously held positions of increasing responsibility at Breakaway Technologies, Inc., Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co.
Amy W. Schulman joined Arsia Therapeutics as chief executive officer in August of 2014, at the same time she began her role as a venture partner at Polaris Partners. Ms. Schulman is also a senior lecturer at Harvard Business School, where she was appointed to the faculty in July of 2014. Prior to this, she joined Pfizer Inc. in 2008 and served as executive vice president and general counsel and the business unit lead for Pfizer’s Consumer Healthcare business until December 2013. Before joining Pfizer, she was a partner at DLA Piper, where she was a member of the Board and Executive Policy Committees. Ms. Schulman is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School in 1989. She serves on the Board of Directors of Alnylam, The Brookings Institution and Wesleyan University.
Dr. Tzianabos formerly served as president and chief scientific officer of OvaScience, Inc. Dr. Tzianabos has more than 20 years of experience in drug discovery and development, strategic planning, portfolio management, business development and alliance management. He joined OvaScience from Shire plc, where he served as senior vice president and head, Research and Nonclinical Early Development. Prior to Shire, Dr. Tzianabos was an associate professor of medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. During his time at Harvard, Dr. Tzianabos served as a consultant to several biotechnology and pharmaceutical companies, including Genzyme Corporation and Eli Lilly. Dr. Tzianabos has published more than 80 scientific papers, reviews, book chapters, and patents. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.